306 related articles for article (PubMed ID: 19732003)
21. p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer.
Anderson KS; Wong J; Vitonis A; Crum CP; Sluss PM; Labaer J; Cramer D
Cancer Epidemiol Biomarkers Prev; 2010 Mar; 19(3):859-68. PubMed ID: 20200435
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: a prospective case-control study in a Korean population.
Kim YM; Whang DH; Park J; Kim SH; Lee SW; Park HA; Ha M; Choi KH
Clin Chem Lab Med; 2011 Mar; 49(3):527-34. PubMed ID: 21320028
[TBL] [Abstract][Full Text] [Related]
23. MMP3 in Comparison to CA 125, HE4 and the ROMA Algorithm in Differentiation of Ovarian Tumors.
Cymbaluk-Ploska A; Chudecka-Glaz A; Surowiec A; Pius-Sadowska E; Machalinski B; Menkiszak J
Asian Pac J Cancer Prev; 2016; 17(5):2597-603. PubMed ID: 27268637
[TBL] [Abstract][Full Text] [Related]
24. The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?
Montagnana M; Danese E; Ruzzenente O; Bresciani V; Nuzzo T; Gelati M; Salvagno GL; Franchi M; Lippi G; Guidi GC
Clin Chem Lab Med; 2011 Mar; 49(3):521-5. PubMed ID: 21288178
[TBL] [Abstract][Full Text] [Related]
25. Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer.
Lowe KA; Shah C; Wallace E; Anderson G; Paley P; McIntosh M; Andersen MR; Scholler N; Bergan L; Thorpe J; Urban N; Drescher CW
Cancer Epidemiol Biomarkers Prev; 2008 Sep; 17(9):2480-7. PubMed ID: 18768519
[TBL] [Abstract][Full Text] [Related]
26. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma.
Hellström I; Raycraft J; Hayden-Ledbetter M; Ledbetter JA; Schummer M; McIntosh M; Drescher C; Urban N; Hellström KE
Cancer Res; 2003 Jul; 63(13):3695-700. PubMed ID: 12839961
[TBL] [Abstract][Full Text] [Related]
27. Serum HE4 Level as a Biomarker to Predict the Recurrence of Gynecologic Cancers.
Li J; Chen H; Curcuru JR; Patel S; Johns TO; Patel D; Qian H; Jiang SW
Curr Drug Targets; 2017; 18(10):1158-1164. PubMed ID: 28382859
[TBL] [Abstract][Full Text] [Related]
28. Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms.
Hellstrom I; Heagerty PJ; Swisher EM; Liu P; Jaffar J; Agnew K; Hellstrom KE
Cancer Lett; 2010 Oct; 296(1):43-8. PubMed ID: 20381233
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic Performance of Serum Human Epididymis Protein 4 (HE4) for Prediction of Malignancy in Ovarian Masses.
Dewan R; Dewan A; Jindal M; Bhardawaj M
Asian Pac J Cancer Prev; 2019 Apr; 20(4):1103-1108. PubMed ID: 31030480
[TBL] [Abstract][Full Text] [Related]
30. Integration of cell phone imaging with microchip ELISA to detect ovarian cancer HE4 biomarker in urine at the point-of-care.
Wang S; Zhao X; Khimji I; Akbas R; Qiu W; Edwards D; Cramer DW; Ye B; Demirci U
Lab Chip; 2011 Oct; 11(20):3411-8. PubMed ID: 21881677
[TBL] [Abstract][Full Text] [Related]
31. The role of human epididymis protein 4 as a biomarker in gynecologic malignancies.
Plotti F; Scaletta G; Terranova C; Montera R; De Cicco Nardone C; Luvero D; Rossini G; Gatti A; Schirò T; Moncelli M; Guzzo F; Angioli R
Minerva Ginecol; 2019 Feb; 71(1):36-43. PubMed ID: 30318876
[TBL] [Abstract][Full Text] [Related]
32. HE4 in ovarian cancer: from discovery to clinical application.
Montagnana M; Danese E; Giudici S; Franchi M; Guidi GC; Plebani M; Lippi G
Adv Clin Chem; 2011; 55():1-20. PubMed ID: 22126021
[TBL] [Abstract][Full Text] [Related]
33. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass.
Moore RG; McMeekin DS; Brown AK; DiSilvestro P; Miller MC; Allard WJ; Gajewski W; Kurman R; Bast RC; Skates SJ
Gynecol Oncol; 2009 Jan; 112(1):40-6. PubMed ID: 18851871
[TBL] [Abstract][Full Text] [Related]
34. Designing early detection programs for ovarian cancer.
Hartge P
J Natl Cancer Inst; 2010 Jan; 102(1):3-4. PubMed ID: 20042718
[No Abstract] [Full Text] [Related]
35. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C
PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095
[TBL] [Abstract][Full Text] [Related]
36. Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women.
Holcomb K; Vucetic Z; Miller MC; Knapp RC
Am J Obstet Gynecol; 2011 Oct; 205(4):358.e1-6. PubMed ID: 21722869
[TBL] [Abstract][Full Text] [Related]
37. Tissue CA125 and HE4 Gene Expression Levels Offer Superior Accuracy in Discriminating Benign from Malignant Pelvic Masses.
Fawzy A; Mohamed MR; Ali MA; Abd El-Magied MH; Helal AM
Asian Pac J Cancer Prev; 2016; 17(1):323-33. PubMed ID: 26838232
[TBL] [Abstract][Full Text] [Related]
38. Comparison of different ovarian cancer detection algorithms.
Macuks R; Baidekalna I; Donina S
Eur J Gynaecol Oncol; 2011; 32(4):408-10. PubMed ID: 21941963
[TBL] [Abstract][Full Text] [Related]
39. The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125?
Nossov V; Amneus M; Su F; Lang J; Janco JM; Reddy ST; Farias-Eisner R
Am J Obstet Gynecol; 2008 Sep; 199(3):215-23. PubMed ID: 18468571
[TBL] [Abstract][Full Text] [Related]
40. Ovarian tumor marker HE4 is differently expressed during the phases of the menstrual cycle in healthy young women.
Anastasi E; Granato T; Marchei GG; Viggiani V; Colaprisca B; Comploj S; Reale MG; Frati L; Midulla C
Tumour Biol; 2010 Oct; 31(5):411-5. PubMed ID: 20490961
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
